Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Certis Oncology Partners With Reveal Biosciences to Offer Advanced Pre-Clinical Oncology Services | ||
By: Nasdaq / GlobeNewswire - 13 Aug 2018 | Back to overview list |
|
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Certis Oncology Solutions and Reveal Biosciences today announced a strategic partnership in which the two companies will collaborate to provide an innovative, next-generation suite of pre-clinical oncology services. Under the agreement, Reveal will leverage its Artificial Intelligence (AI)-based pathology tools to generate advanced analytics that quantify biomarkers in human tumor tissue grown in immunodeficient mice using Certis’ Orthotopic PDX (Patient-Derived Xenograft) technique. The combined services will also feature Tissue Micro Arrays (TMAs), which enable multiple Orthotopic PDX tumors to be analyzed at the same time. TMAs are a quick and reliable method for providing valuable data to companies developing new drugs. “We have been working closely with Certis for some time and are delighted to formalize the relationship today,” said Claire Weston, Ph.D., Founder and CEO of Reveal Biosciences. “With their ability to grow Orthotopic PDX tumors in mice at a high rate and replicate patient outcomes, Certis mouse models are more clinically relevant than standard PDXs. This provides a critical new class of data for cancer drug development.” “Reveal’s quantitative histopathology services and AI-based pathology analysis provide an ideal foundation for researching the characteristics of Orthotopic PDX-based tumors,” agreed Peter Ellman, CEO of Certis Oncology. “Their AI-based tissue analysis utilizes trained pathology models to recognize disease patterns and quantify biomarkers in whole slide digital images to benefit translational oncology research.” Combining the Latest Techniques Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and in situ hybridization (ISH) to generate enhanced data from tissue samples. Reveal is also generating disease-specific AI-based models as pathology decision support diagnostics to benefit patients and accelerate clinical trials. Certis is a new precision medicine company focused on individualized patient care. Certis’ services are based on a technique known as Orthotopic PDX (Patient-Derived Xenografts). In Greek, orthotopic means “the correct place.” The orthotopic technique takes a very small specimen of the human patient’s tumor and surgically implants it into the corresponding anatomic location (pancreas, liver, lung, etc.) in immunodeficient mice. Concurrent testing of multiple drugs enabled by Orthotopic PDX models presents oncologists with more treatment options – while reducing the time required to select each patient’s optimal treatment. About Certis Oncology Solutions About Reveal Biosciences Certis Oncology: Media and Investors Contact Reveal Biosciences: Media Contact |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |